Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 6/20 | 0.72 |
| ▸ | CBX7 | O95931 | 4/20 | 0.72 |
| ▸ | CBX8 | Q9HC52 | 4/20 | 0.72 |
| ▸ | CBX4 | O00257 | 3/20 | 0.72 |
| ▸ | CBX6 | O95503 | 1/20 | 0.63 |
| ▸ | CBX2 | Q14781 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23815823 | 1.00 | CDYL2 (0.72) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23718040 | 0.91 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL26219950 | 0.91 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23682865 | 0.91 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23717921 | 0.91 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23682719 | 0.91 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23718039 | 0.90 | CDYL2 (0.75) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23815796 | 0.90 | CDYL2 (0.75) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL25049665 | 0.88 | CDYL2 (0.72) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL24510752 | 0.84 | CDYL2 (0.78) | CDYL2CBX7CBX8CBX4CBX6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163028-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-05-22 | — | — | US | disclosed |
| US-12018253-B2 | Method of detecting Polycomb Repressive Complex activity | IMBA—INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH (AT) | 2024-06-25 | — | — | US | disclosed |
| EP-3602047-B1 | METHOD OF DETECTING POLYCOMB REPRESSIVE COMPLEX ACTIVITY | IMBA INST MOLEKULARE BIOTECH (AT) | 2023-10-25 | — | — | EP | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | CDYL2 1804/4885CBX7 1030/4885CBX8 1268/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDYL2 621/4885CBX7 1336/4885CBX8 541/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CDYL2 139/4885CBX7 1122/4885CBX8 492/4885 |
| US-20250163028-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | UBQLN2, NEDD4, UBTF | CDYL2 1134/4885CBX7 1488/4885CBX8 1090/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | CDYL2 1159/4885CBX7 1599/4885CBX8 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.